Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 9,138 matching trials from the live ClinicalTrials.gov search.
Filters: Rochester, Minnesota Clear all
Completed No phase listed Observational Accepts healthy volunteers

Histology of Functional Density in Premenopausal Breast

NCT01588834
View directory record Official record
Conditions
Dense Breasts, Breast Cancer
Interventions
breast biopsy
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 55 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 31, 2026, 2:14 PM EDT
Recruiting Phase 1 Interventional

A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer

NCT04521764
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Breast Adenocarcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein, Computed Tomography, Magnetic Resonance Imaging, Biopsy, Biospecimen Collection
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 31, 2026, 2:14 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

NCT04703192
View directory record Official record
Conditions
Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma
Interventions
Valemetostat Tosylate
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
Duarte, California • Palo Alto, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 31, 2026, 2:14 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

NCT06734234
View directory record Official record
Conditions
Kidney Disease
Interventions
GSK4771261, Placebo matching GSK4771261
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
25 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 31, 2026, 2:14 PM EDT
Enrolling by invitation Phase 4 Interventional

Antibiotic Prophylaxis in High-Risk Arthroplasty Patients

NCT04297592
View directory record Official record
Conditions
Infections Joint Prosthetic, Overweight or Obesity, MSSA Colonization, MRSA, Chronic Kidney Diseases, Diabetes, Autoimmune Diseases, Inflammatory Disease, Tobacco Use
Interventions
Cephalexin, Doxycycline, Cefadroxil
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
4,618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Iowa City, Iowa • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 31, 2026, 2:14 PM EDT
Completed No phase listed Observational

Genomics of Primary Sclerosing Cholangitis (PSC)

NCT01161992
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
Genetic Analysis
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
5 Years to 90 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 31, 2026, 2:14 PM EDT
Completed Not applicable Interventional

Scrambler Therapy in Treating Chronic Pain in Patients With Rash From Varicella Zoster Virus Infection

NCT01347736
View directory record Official record
Conditions
Dermatologic Complications, Pain, Viral Infection
Interventions
scrambler therapy, questionnaire administration, dermatologic complications management/prevention
Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 31, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Results available

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

NCT01979536
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Interventions
Brentuximab Vedotin, Crizotinib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
154
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 117 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 31, 2026, 2:14 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans

NCT06972407
View directory record Official record
Conditions
Genetic Predisposition, Type2diabetes
Interventions
Exendin 9-39, Saline
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 31, 2026, 2:14 PM EDT
Completed Not applicable Interventional Results available

X-3 Polyethylene Survival Outcomes Study

NCT00493792
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee, Total Knee Replacement
Interventions
X3 Polyethylene, N2Vac Polyethylene
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 85 Years
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 31, 2026, 2:14 PM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

NCT02864953
View directory record Official record
Conditions
Brain Edema, Stroke, Acute
Interventions
BIIB093, Placebo
Drug
Lead sponsor
Remedy Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
74
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 31, 2026, 2:14 PM EDT
Withdrawn No phase listed Observational

The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study

NCT02736357
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
8
States / cities
Miami, Florida • Atlanta, Georgia • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 31, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome

NCT00514501
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Iodofiltic acid I 123
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
40 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
36
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Oct 31, 2026, 2:14 PM EDT
Completed Phase 2 Interventional

Melatonin and Radiation Therapy in Treating Patients With Brain Metastases

NCT00031967
View directory record Official record
Conditions
Metastatic Cancer, Radiation Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
therapeutic melatonin, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
0 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
215
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 31, 2026, 2:14 PM EDT
Recruiting Phase 1 Interventional

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

NCT06375044
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
SIM0500
Drug
Lead sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Phoenix, Arizona • Orange, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 31, 2026, 2:14 PM EDT
Recruiting Phase 3 Interventional

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

NCT06022939
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bortezomib, Computed Tomography, Cyclophosphamide, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Echocardiography, Magnetic Resonance Imaging, Melphalan, Positron Emission Tomography, Stem Cell Isolation, Survey Administration
Procedure · Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
117
States / cities
Goodyear, Arizona • Tucson, Arizona • Duarte, California + 93 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 31, 2026, 2:14 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia

NCT00002912
View directory record Official record
Conditions
Leukemia
Interventions
etoposide, mitoxantrone hydrochloride, valspodar
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
50
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 31, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Results available

SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes

NCT02048371
View directory record Official record
Conditions
Liposarcoma, Osteogenic Sarcoma, Ewing/Ewing-like Sarcoma, Rhabdomyosarcoma, Mesenchymal Chondrosarcoma
Interventions
Regorafenib, Placebo
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
5 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
18
States / cities
Duarte, California • Los Angeles, California • Santa Monica, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 31, 2026, 2:14 PM EDT
Withdrawn Phase 2 Interventional

Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI)

NCT05269134
View directory record Official record
Conditions
Prosthetic Joint Infection
Interventions
Bacteriophage, Placebo
Drug
Lead sponsor
Adaptive Phage Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
San Diego, California • Hartford, Connecticut • Idaho Falls, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 31, 2026, 2:14 PM EDT
Recruiting Phase 2 Interventional

Platform Clinical Study for Conquering Scleroderma

NCT06195072
View directory record Official record
Conditions
Interstitial Lung Disease Due to Systemic Disease, Scleroderma
Interventions
Amlitelimab, BI 1015550 (Nerandomilast), Placebo
Drug
Lead sponsor
Scleroderma Research Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 31, 2026, 2:14 PM EDT
Recruiting Phase 2 Interventional

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

NCT05910801
View directory record Official record
Conditions
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lenalidomide, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography, Tafasitamab, Venetoclax
Procedure · Drug · Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 31, 2026, 2:14 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

NCT02678312
View directory record Official record
Conditions
Pediatric Heart Failure
Interventions
LCZ696, Enalapril, Placebo of LCZ696, Placebo of Enalapril
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
25
States / cities
Loma Linda, California • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 31, 2026, 2:14 PM EDT
Terminated Phase 2 Interventional Results available

Long-term Safety Study of Brodalumab in Adults With Crohn's Disease

NCT01199302
View directory record Official record
Conditions
Crohn's Disease
Interventions
Brodalumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
Not listed
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
11
States / cities
Birmingham, Alabama • Jacksonville, Florida • Hammond, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Oct 31, 2026, 2:14 PM EDT
Completed Phase 2 Interventional

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

NCT00075439
View directory record Official record
Conditions
Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Pancreatic Polypeptide Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma, WDHA Syndrome
Interventions
gefitinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 31, 2026, 2:14 PM EDT